Coherus BioSciences Plunges 13.73% on Flat Q1 Revenue

On May 13, 2025, Coherus Biosciences experienced a significant drop of 13.73% in pre-market trading, reflecting investor sentiment amidst recent developments and financial reports.

Coherus BioSciences reported its Q1 2025 earnings, revealing a flat revenue of $7.3 million despite a 15% growth in patient demand. The company also initiated a Phase 1b CHS-114/toripalimab combination dose optimization study in 2L HNSCC, with the first data readout expected in Q2 2026.

The company's strategic shift towards oncology, including the divestiture of its UDENYCA franchise, has positioned it for future growth. Key financial metrics for the quarter included net revenue from continuing operations of $7.6 million, driven by LOQTORZI sales, and a net loss from continuing operations of $47.4 million, showing an improvement from the previous year’s loss.

Coherus BioSciences is actively advancing its oncology pipeline, with ongoing studies for CHS-114 and casdozokitug in various cancer indications. The company is also exploring partnerships to expand LOQTORZI’s label and enhance its market presence. Looking ahead, Coherus BioSciences is poised to leverage its innovative oncology portfolio to drive growth and improve cancer treatment outcomes, with key data milestones anticipated in 2026.